Eltrombopag Tablet
Product Images NDC 70710-1397
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Eltrombopag (NDC 70710-1397). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
12.5mg (989cf54a C1e9 4e41 967b 295d45cbf5b7 02)
This is a pharmacy label for Eltrombopag tablets, with instructions to swallow the tablets whole without splitting, chewing, or crushing them. The label includes dosage information and storage instructions. The pharmacist is advised to dispense the medication guide to each patient separately. Safety precautions are outlined, including keeping the medication out of reach of children and not using if the safety seal under the cap is broken or missing. The package is child-resistant, and the tablets contain a certain amount of Eltrombopag active ingredient per tablet. The text provides contact information for medication guides or inquiries. The product is distributed by Zydus Pharmaceuticals (USA) Inc.*
25mg (989cf54a C1e9 4e41 967b 295d45cbf5b7 03)
This text appears to be a product label for Eltrombopag tablets containing essential information like dosage instructions, storage conditions, and safety precautions. Each tablet contains Eltrombopag olamine equivalent to 25 mg of Eltrombopag. It is advised to swallow the tablets whole and not split, chew, or crush them. The package is child-resistant and should be stored at a temperature range of 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C and 30°C (59°F to 86°F). Pharmacies are urged to dispense the medication guide provided separately for each patient. Additionally, it mentions the importance of using safety precautions during dispensing and keeping all drugs out of children's reach. For further details, a Medication Guide is available online or via a contact number provided by the manufacturer.*
50mg (989cf54a C1e9 4e41 967b 295d45cbf5b7 04)
This is a description of a medication called Eltrombopag in tablet form, with each tablet containing 50 mg of the active ingredient. The instructions state to swallow the tablets whole, without splitting, chewing, or crushing them. It comes in a package of 30 tablets and should be stored at a temperature between 20°C to 25°C. The packaging is child-resistant, and it warns to keep it out of reach of children and not to use if the safety seal is broken. The medication guide is available for further reference, and it is distributed by Zydus Pharmaceuticals (USA) Inc.*
75mg (989cf54a C1e9 4e41 967b 295d45cbf5b7 05)
This text appears to be a medication label for Eltrombopag tablets. The label instructs to swallow the tablets whole and not split, chew, or crush them. It also provides dosage information and storage instructions. Additionally, the label emphasizes the importance of keeping the medication and all drugs out of the reach of children and to not use if the printed safety seal under the cap is broken or missing.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.